Expert consensus to optimize the treatment of elderly patients with luminal metastatic breast cancer

• Published in: Clinical & translational oncology Vol. 24; no. 6; pp. 1033 - 1046
• Main Authors: Torregrosa-Maicas, M. D., del Barco-Berrón, S., Cotes-Sanchís, A., Lema-Roso, L., Servitja-Tormo, S., Gironés-Sarrió, R.
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01-06-2022
• Subjects: Age Factors; Aged; Breast - pathology; Breast Neoplasms - drug therapy; Breast Neoplasms - metabolism; Consensus; Female; Geriatric Assessment; Humans; Medicine; Medicine & Public Health; Oncology; Quality of Life; Receptor, ErbB-2; Special; Special Article; mTOR inhibitors; Hormone therapy; PI3K inhibitors; Cyclin inhibitors; PARP inhibitors; Geriatrics
• ISSN: 1699-3055; 1699-048X; 1699-3055
• DOI: 10.1007/s12094-021-02766-8

Most patients diagnosed with luminal metastatic breast cancer (MBC) who are seen in oncology consultations are elderly. MBC in elderly patients is characterized by a higher percentage of hormone receptor (HR) expression and a lower expression of human epidermal growth factor receptor 2 (HER2). The decision regarding which treatment to administer to these patients is complex due to the lack of solid evidence to support the decision-making process. The objective of this paper is to review the scientific evidence on the treatment of elderly patients with luminal MBC. For this purpose, the Oncogeriatrics Section of the Spanish Society of Medical Oncology (SEOM), the Spanish Breast Cancer Research Group (GEICAM) and the SOLTI Group appointed a group of experts who have worked together to establish consensus recommendations to optimize the treatment of this population. It was concluded that the chronological age of the patient alone should not guide therapeutic decisions and that a Comprehensive Geriatric Assessment (CGA) should be performed whenever possible before establishing treatment. Treatment selection for the elderly population should consider the patient’s baseline status, the expected benefit and toxicity of each treatment, and the impact of treatment toxicity on the patient’s quality of life and functionality.